Please login to the form below

Not currently logged in

Biogen's Douglas Williams departs for biotech start-up

Research head will be first member of a new cancer-focused firm

Biogen Douglas WilliamsDouglas Williams will this week leave Biogen for a new role as CEO of an as-yet unnamed biotech start-up that will focus on cancer diagnostics and therapies.

Williams had led Biogen's R&D  since 2011 as executive vice president of research and development, prior to which his industry roles included a six year stint at Seattle-based biotech Zymogenetics (now part of BMS), where he rose to be its CEO.

He said: “While I am sad to leave Biogen I am excited about the opportunity to follow a real passion of mine. I am proud of the progress of the company's R&D organisation and am pleased that it will be in very capable hands.”

Williams will be replaced by chief medical officer Alfred Sandrock and chief scientific officer Spyros Artavanis-Tsakonas, who will be handed joint responsibility for Biogen Research and Development.

Biogen's CEO George Scangos said: “All of us at Biogen appreciate Doug's contributions to the rapid development of our Research and Development organisation.

“We are fortunate to have Al Sandrock and Spyros Artavanis-Tsakonas to lead the work to which Biogen is dedicated.”

27th July 2015

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?
The Biosimilar Challenge